Transcode Therapeutics Inc
RNAZ8.910USD
-1.060-10.63%
終値 02/06, 16:00（ET）15分遅れの株価
7.43M時価総額
損失額直近12ヶ月PER
詳細情報 Transcode Therapeutics Inc 企業名
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Incの企業情報
企業コードRNAZ
会社名Transcode Therapeutics Inc
上場日Apr 28, 2021
最高経営責任者「CEO」Calais (Philippe P)
従業員数7
証券種類Ordinary Share
決算期末Apr 28
本社所在地6 Liberty Square
都市BOSTON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02109
電話番号18573016857
ウェブサイトhttps://www.transcodetherapeutics.com/
企業コードRNAZ
上場日Apr 28, 2021
最高経営責任者「CEO」Calais (Philippe P)
Transcode Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
+1.00%
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
+1.00%
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Fri, Jan 9
更新時刻: Fri, Jan 9
株主統計
種類
株主統計
株主統計
比率
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
DRW Securities, LLC
1.28%
The Vanguard Group, Inc.
0.71%
Geode Capital Management, L.L.C.
0.58%
他の
83.82%
株主統計
株主統計
比率
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
DRW Securities, LLC
1.28%
The Vanguard Group, Inc.
0.71%
Geode Capital Management, L.L.C.
0.58%
他の
83.82%
種類
株主統計
比率
Corporation
9.08%
Investment Advisor/Hedge Fund
5.11%
Investment Advisor
2.31%
Research Firm
0.28%
Individual Investor
0.14%
Hedge Fund
0.02%
他の
83.06%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
36
70.82K
7.72%
-29.38K
2025Q3
37
40.93K
4.61%
-48.04K
2025Q2
41
77.84K
18.97%
+69.48K
2025Q1
45
80.09K
9.69%
+74.47K
2024Q4
36
155.76K
22.37%
+143.23K
2024Q3
40
10.06K
1.97%
-8.53K
2024Q2
41
8.22K
4.45%
-5.03K
2024Q1
41
12.92K
7.67%
+11.92K
2023Q4
41
826.00
4.24%
+40.00
2023Q3
39
727.00
50.61%
+276.00
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
CK Life Sciences International Holdings, Inc.
83.28K
9.08%
+83.28K
--
Oct 27, 2025
Sabby Management, LLC
41.60K
4.54%
+41.60K
--
Dec 31, 2025
DRW Securities, LLC
11.70K
1.28%
+11.70K
--
Sep 30, 2025
The Vanguard Group, Inc.
6.54K
0.71%
--
--
Nov 30, 2025
Geode Capital Management, L.L.C.
4.93K
0.54%
--
--
Nov 30, 2025
Citi Investment Research (US)
1.59K
0.17%
+1.59K
--
Sep 30, 2025
Tracy (Thomas Joseph)
1.25K
0.14%
+1.25K
--
Mar 07, 2025
Desjardins Securities Inc.
975.00
0.11%
+975.00
--
Sep 30, 2025
Tower Research Capital LLC
142.00
0.02%
-260.00
-64.68%
Sep 30, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
日付
配当落ち日
種類
比率
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
May 22, 2023
Merger
20→1
詳細を見る
